Templeton Growth Fund Bets Big on Clorox and Alibaba—Waiting for the Market to Wake Up

The Templeton Growth Fund's approach is defined by a single, deliberate choice: deep conviction in a few exceptional businesses. Its portfolio is not scattered; it is focused. The fund's top three positions now represent 82% of the portfolio. This is not a tactical error or a sign of weakness. It is the core of the strategy, a concentrated exposure to businesses the team believes offer asymmetric risk/reward at current prices.

This concentration is an intentional bet on the power of deep research and long-term compounding. The fund's managers are willing to accept higher volatility in exchange for the potential to capture outsized returns from their most compelling ideas. They measure success not by quarterly performance, but by the resolution of fundamental dislocations over a 3-5 year period. This long lens is what allows them to act with discipline, as seen in their recent moves to buy Clorox during an operational crisis and hold Alibaba through political noise.

The philosophy is straightforward. It is a belief that a handful of profoundly misunderstood or temporarily distressed companies can deliver returns that far exceed those of a broadly diversified portfolio. The fund's commentary frames this as a test of patience, a necessary quality when the market's short-term focus can obscure the true value of a durable business. For the Templeton Growth Fund, concentration is the vehicle for patience, and patience is the path to realizing intrinsic value.

Valuation and the Width of the Moat

The fund's concentrated bets are not a gamble on fleeting trends. They are a disciplined application of value investing principles, where the quality of the underlying business-its competitive moat-is paramount. The managers are not chasing growth at any price; they are seeking durable advantages that can compound over time, even when the market is distracted.

Their recent actions reveal this focus. The decision to buy Clorox during an operational ERP crisis is a classic bet on a wide moat. The company's brand strength and entrenched position in household essentials provide a durable advantage that can weather temporary operational dislocations. The fund's patience in holding Alibaba through political headlines reflects a similar calculus. Despite facing significant regulatory headwinds, the underlying consumer internet business in China possesses a powerful network effect and scale that the managers believe will eventually reassert itself. In both cases, the market's short-term noise is being used as a source of opportunity, not a reason for panic.

This discipline extends to what they are choosing not to buy. The fund's commentary explicitly notes its decision to stay out of AI infrastructure at 40x earnings. This is a textbook value move. At those multiples, the margin of safety-the buffer between price and intrinsic value-is effectively nonexistent. The fund's philosophy is to avoid paying a premium for growth when the risk/reward equation is no longer favorable. Instead, they seek businesses with proven moats where the price paid offers a more reasonable cushion.

The bottom line is that the Templeton Growth Fund's portfolio is a collection of businesses with wide moats, bought at prices that reflect a margin of safety. Their concentration amplifies this strategy, forcing a rigorous focus on quality. The fund's patience is not passive waiting; it is active waiting for the market to recognize the true, durable value of these exceptional companies.

Performance Context and Investor Discipline

The Templeton Growth Fund's strategy is being tested by a market that has recently shown little appetite for long-term bets. Global equity markets consolidated in the fourth quarter of 2025, posting moderate gains after a stronger advance earlier in the year Markets: Global equity markets collectively posted moderate gains in the fourth quarter of 2025, marking a period of consolidation after the stronger advance seen in the third quarter. This environment of calm and stability is the opposite of the volatility that often creates the deepest bargains. It is a period where patience is harder to muster, as the market's focus remains on near-term earnings and quarterly results.

The fund's current share price of $26.66 on March 24, 2026, is the market's direct valuation of this concentrated, patient approach. It reflects a price that has not yet been rewarded for the fund's recent, contrarian moves. The strategy's success is explicitly contingent on ignoring this near-term noise. As the fund's commentary states, the decisions to buy Clorox during an operational crisis or hold Alibaba through political headlines won't be validated by next quarter's performance-they'll be measured over the next 3-5 year period where dislocations resolve and valuations matter.

For an investor, this creates a clear but demanding setup. The fund's performance will likely remain muted during periods of market consolidation, as its concentrated holdings are not being bid up for short-term momentum. The challenge is to maintain conviction when the market's rhythm is slow and the payoff horizon is measured in years. The fund's philosophy is a direct challenge to the prevailing market psychology, which often rewards speed and reaction. In this context, the fund's discipline is not just a portfolio construction choice; it is a requirement for the investor's own temperament. The price of admission is a long-term horizon and the willingness to wait.

Catalysts and Risks to the Thesis

The Templeton Growth Fund's concentrated, patient strategy operates on a simple but demanding premise: the market's short-term noise creates opportunities, but the payoff requires a long-term view. The catalysts that could validate this approach are directly tied to the resolution of the very dislocations the fund is betting on. For Clorox, the primary catalyst is the successful completion of its ERP transition, which should restore operational efficiency and allow the company's wide consumer staples moat to drive earnings growth. For Alibaba, the catalyst is a stabilization and normalization of its regulatory environment in China, which would allow its dominant consumer internet platform to re-accelerate. In both cases, the fund's patience is being rewarded with a lower entry price, and the payoff hinges on the market eventually recognizing the underlying business strength once the temporary overhang lifts.

The flip side of this concentrated bet is a significant risk: the portfolio's high volatility. With the top three holdings representing 82% of the portfolio, the fund's performance is heavily dependent on the fortunes of just a few names. This concentration will drive volatility, a fact the managers acknowledge as part of their conviction. For an investor, this means the strategy is ill-suited for those with a short-term horizon or a low tolerance for swings. The fund's price action will likely remain muted during periods of market consolidation, as seen in the recent fourth quarter, and could experience sharper declines if any of the key holdings face further setbacks. The risk here is not just financial; it is psychological, as the discipline required to hold through such volatility is a high bar for many.

Ultimately, the fund's success depends on its ability to maintain the same disciplined valuation approach that guided its recent moves. The commentary notes its decision to stay out of AI infrastructure at 40x earnings as a key example of this. The risk to the thesis is that, over time, the temptation to chase popular, high-flying sectors could erode this margin-of-safety discipline. If the fund were to deploy capital at stretched valuations, it would undermine the very foundation of its strategy. The catalysts are the positive outcomes of patience; the risks are the consequences of a lack of it. The fund's long-term success will be measured by its unwavering commitment to buying exceptional businesses at reasonable prices, regardless of the market's current mood.